NASDAQ:BOLD - Audentes Therapeutics Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $38.50 0.00 (0.00 %) (As of 03/20/2019 04:00 PM ET)Previous Close$38.50Today's Range$37.76 - $39.115552-Week Range$17.95 - $46.18Volume499,588 shsAverage Volume525,491 shsMarket Capitalization$1.64 billionP/E Ratio-11.32Dividend YieldN/ABeta1.9 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Audentes Therapeutics (NASDAQ:BOLD) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.11 Wall Street analysts have issued ratings and price targets for Audentes Therapeutics in the last 12 months. Their average twelve-month price target is $33.99, suggesting that the stock has a possible downside of 11.71%. The high price target for BOLD is $49.00 and the low price target for BOLD is $20.00. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyHoldHoldHoldConsensus Rating Score: 2.552.452.252.42Ratings Breakdown: 1 Sell Rating(s)3 Hold Rating(s)7 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)4 Hold Rating(s)6 Buy Rating(s)0 Strong Buy Rating(s)2 Sell Rating(s)5 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)2 Sell Rating(s)3 Hold Rating(s)7 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $33.99$32.2122$33.2122$35.4545Price Target Upside: 11.71% downside30.41% upside42.30% upside4.41% downsideAudentes Therapeutics (NASDAQ:BOLD) Consensus Price Target History Audentes Therapeutics (NASDAQ:BOLD) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails3/18/2019HC WainwrightReiterated RatingBuy$33.00 ➝ $44.00Low2/27/2019William BlairReiterated RatingHoldHigh2/25/2019Chardan CapitalUpgradeNeutral ➝ Buy$35.00 ➝ $40.00High2/1/2019MizuhoReiterated RatingBuy$45.00High1/31/2019CowenReiterated RatingBuyMedium1/11/2019GuggenheimUpgradeNeutral ➝ Buy$35.00High12/10/2018CitigroupLower Price TargetNeutral ➝ Neutral$40.00 ➝ $28.00Low12/2/2018JPMorgan Chase & Co.Initiated CoverageOverweight$23.91High11/7/2018Raymond JamesReiterated RatingHoldHigh11/7/2018B. RileyBoost Price TargetSell$20.00 ➝ $21.00High10/8/2018WedbushLower Price TargetOutperform ➝ Outperform$52.00 ➝ $49.00Low1/5/2018BMO Capital MarketsSet Price TargetBuy$44.00High11/15/2017Leerink SwannReiterated RatingOutperform$22.00 ➝ $29.00N/A9/22/2017Bank of AmericaReiterated RatingBuy$23.00 ➝ $33.00Low8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$23.00Low(Data available from 3/20/2017 forward) This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: What is a short straddle?